Lundbeck rolls out Brintellix in first EU country; Merck KGaA strikes emerging markets deal with Lupin;

@FiercePharma: Top-read in FierceAnimalHealth Mon: FDA seeks input on conditional approvals for new animal health products. Story | Follow @FiercePharma

@EricPFierce: Merck KGaA turns to India's Lupin to manufacture $2B worth of drugs in emerging markets. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Would Ian Read keep his AZ deal promises? U.K. panel eyes new rules to enforce them. ICYMI yesterday | Follow @CarlyHFierce

> The Danish drugmaker Lundbeck launched its new antidepressant Brintellix in its home market, its first roll-out for the new drug in the EU. Report

> Merck KGaA inked a deal with India's Lupin to sell its generic drugs in emerging markets. Report

> The only company making smallpox treatments for U.S. stockpiles, Siga Technologies, filed for bankruptcy to forestall a $232 million damages award to competitor PharmAthene. Report

> Bristol-Myers Squibb's ($BMY) Yervoy won approval in Canada as a first-line treatment for advanced melanoma. Release

> European regulators said they would rule by Oct. 16 on AbbVie's ($ABBV) proposed $52 billion buyout of the Irish drugmaker Shire ($SHPG). Report

> Germany's Stada reaffirmed its prediction that its Russian business, which accounts for about one-fourth of its sales, would take a turn for the better in the fourth quarter. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Danaher cements commitment to dental with $2.2B Nobel acquisition. Article | Follow @FierceMedDev

@MichaelGFierce: Liposome research adds up to better #cancer treatment options. More | Follow @MichaelGFierce

> WSJ: What are the costs and benefits of early cancer screening? Item

> Harvard researchers develop dialysis device to fight Ebola. Story

> Former Alere execs assemble $3.8B take-private offer. Report

Biotech News

@FierceBiotech: Lilly takes the lead on AstraZeneca's Alzheimer's drug in $500M deal. News | Follow @FierceBiotech

@JohnCFierce: Biotech R&D is changing. Don't get left behind. (A shameless plug for upcoming executive breakfast panel in Boston). More | Follow @JohnCFierce

@DamianFierce: Oxygen Bio will soon be Tenax Therapeutics. Release | Follow @DamianFierce

@EmilyMFierce: Great piece on the trials and tribulations of stem cell research. Report from the NYT | Follow @EmilyMFierce

> U.K. picks a controversial brain cancer vaccine as its first new 'innovative medicine.' Story

> Novo's next-gen insulin clears a pediatric hurdle amid renewed U.S. hope. Article

> Smallpox biotech Siga files for bankruptcy over PharmAthene spat. Item

> Parkinson's biotech NeuroDerm joins the IPO queue with a $65M pitch. More

Biotech Research News

> Notable academic-pharma alliances of 2014. Feature

> Geneva Foundation gets $3M NIH grant for Ebola drug work. News

> Protein stops bone loss in arthritic mice. More

> Google's Calico acquires UT Southwestern compounds for neurodegenerative disorders. Story

> $64M NIH initiative will catalog cell responses to drugs. Article

Pharma Manufacturing News

> Gilead hands Sovaldi manufacturing tech to 7 generics makers. Report

> Merck negotiates huge production deal with Lupin. More

> Hikma opens oncology API plant in Jordan. Article

> India's top drugmakers forecast to invest $8B in production upgrades. Item

> Hospira again reports a human hair discovered in a product. Story

And Finally... The Ropes & Gray law firm's Hong Kong office, which represents GlaxoSmithKline ($GSK) and other big drugmakers, hired an assistant U.S. attorney to help clients understand "how U.S. prosecutors" and regulators are thinking. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.